Victory Capital Management Inc. bought a new stake in athenahealth (NASDAQ:ATHN) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 87,470 shares of the health services provider’s stock, valued at approximately $12,511,000. Victory Capital Management Inc. owned about 0.22% of athenahealth at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in ATHN. Virginia Retirement Systems ET AL purchased a new stake in athenahealth during the first quarter valued at about $1,001,000. Trexquant Investment LP purchased a new stake in athenahealth during the first quarter valued at about $420,000. Kornitzer Capital Management Inc. KS grew its position in athenahealth by 16.2% during the first quarter. Kornitzer Capital Management Inc. KS now owns 257,400 shares of the health services provider’s stock valued at $36,816,000 after acquiring an additional 35,810 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its position in athenahealth by 3.0% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 561,940 shares of the health services provider’s stock valued at $80,374,000 after acquiring an additional 16,240 shares during the period. Finally, MUFG Securities EMEA plc purchased a new stake in athenahealth during the first quarter valued at about $4,863,000.
athenahealth opened at $153.25 on Tuesday, Marketbeat reports. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.71 and a current ratio of 2.71. athenahealth has a one year low of $111.61 and a one year high of $158.66. The stock has a market capitalization of $6.06 billion, a P/E ratio of 97.61, a price-to-earnings-growth ratio of 2.79 and a beta of 1.16.
athenahealth (NASDAQ:ATHN) last released its quarterly earnings results on Thursday, April 26th. The health services provider reported $1.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.53. athenahealth had a return on equity of 13.01% and a net margin of 6.77%. The business had revenue of $329.40 million for the quarter, compared to analysts’ expectations of $318.13 million. During the same quarter in the previous year, the firm posted $0.32 earnings per share. The company’s revenue was up 15.4% compared to the same quarter last year. equities research analysts predict that athenahealth will post 2.92 earnings per share for the current year.
In other athenahealth news, Director Jeffrey R. Immelt purchased 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The shares were acquired at an average price of $141.04 per share, for a total transaction of $507,744.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Daniel P. Haley sold 1,107 shares of the business’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $149.40, for a total value of $165,385.80. Following the completion of the transaction, the insider now owns 12,383 shares in the company, valued at approximately $1,850,020.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,431 shares of company stock worth $7,084,565. Insiders own 2.90% of the company’s stock.
A number of equities research analysts have issued reports on ATHN shares. Bank of America started coverage on athenahealth in a research report on Tuesday, February 27th. They set a “neutral” rating and a $147.00 price target for the company. ValuEngine downgraded athenahealth from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. JPMorgan Chase started coverage on athenahealth in a research report on Tuesday, April 24th. They set a “neutral” rating and a $159.00 price target for the company. Royal Bank of Canada set a $136.00 price target on athenahealth and gave the company a “hold” rating in a research report on Monday, April 30th. Finally, Leerink Swann reissued a “hold” rating on shares of athenahealth in a research report on Friday, April 27th. One research analyst has rated the stock with a sell rating, eighteen have given a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $152.43.
athenahealth, Inc, together with its subsidiaries, provides network-based medical record, revenue cycle, patient engagement, care coordination, and population health services for medical groups and health systems. It offers athenaCollector, a network-enabled billing and practice management solution; athenaClinicals, an electronic health record for managing patient's clinical documentation; athenaCommunicator, an engagement and communication solution that provides an automated communication service between patients and provider practices for interactions outside the exam room; and athenaCoordinator for order transmission and care coordination services.
Want to see what other hedge funds are holding ATHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for athenahealth (NASDAQ:ATHN).
Receive News & Ratings for athenahealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth and related companies with MarketBeat.com's FREE daily email newsletter.